Bottom line: MeAgain is better when the GLP-1 journey should be the product, not one feature inside a broader program
In addition to GLP-1R agonists, orally administrated DPP4-inhibitors, e.g., sitagliptin and saxagliptin , which are known to potentiate the effect of endogenous GLP-1 by inhibiting its degradation, have also been clinically studied as protective agents against retinopathy (Chung et al., 2016), Alzheimers disease (Isik et al., 2017), and Parkinsons disease (Svenningsson et al., 2016) in T2D patients, although DPP4-inhibitors cannot cross the blood-brain barrier (Mousa and Ayoub, 2019)
While COVID-19 is predominantly a respiratory disease, growing evidence shows that patients with pre-existing cardiovascular disease (CVD) are at higher risk of developing more severe COVID-19, while post-COVID-19 infection, individuals may be prone to CVD 1,2,3
A preferred melanocortin receptor agonist is PT-141 , and a preferred non-oral administration thereof is by intranasal (IN) administration
95% CI, 0.71-0.77)
doi:10.1001/jama.296.1.87
